Yeah right. Read the news release. Dodd is going to focus on trying to deliver a single dollar of profit after 26 years in the business. He's on corporate welfare and selling vaginal gel for a loss. Never heard of a business with a life over 26 years and nothing to show for it. He crooked the newbies for their life savings before reverse #$%$ on them twice in 3 years.
This Emperor Wears No Clothes! Junior is off to stock up Dodd's Carolina beach house with plenty of toilet paper. If they run out of the paper then they'll use stock certificates!!!
You obviously get paid to post total nonsense. There is no deal on the table. Nice try of conning honest investors to pay Dodd's salary. Idiot!!!
There is not a single voice to effectively argue for/against the AEZS drugs. Dodd has everyone guessing. If he comes up short, he may lie for why it was a failure and how much more dilution the company will need for Phase 3's? Gas bagging at this point of time is not a card he can afford to play again.
Btw, when do you think that the AEZS drugs will realistically come to market, and why?
Removing VaggieGel out of the marketed products, because it was a complete marketing failure and Dodd will assure us that 'it didn't fit our core business model'
If you are referring to AEZS, 148k shares ain't a whole lot of dumping. If you are referring to the stock market then yes, it was a dumpy day. If you are referring to what's happening in your house, I don't want to read about it!
Exactly! It reminds me of the silly little school children who grew up to be senseless morons. This person can't even read a financial report or a balance statement, but just keeps going on insanely with childish drivel; 'the stock is going to be 20, it's going to 50, yada yada' with no base to support such nonsense except that a couple of drugs have been in phase 3 for several years and that the contract sales force can't even make money selling vaginal jelly. Talk about someone hoping that others will get him a little richer overnight!
Do you think that Dodd can actually build trust again so easily after he thoroughly creamed the shareholders on that #$%$ finance deal from last year? When he said it was such a good deal only to admit his flunky failure six months later? Would any sane person believe such a two face? Jacking up the OS to 1.2 billion pre split and then doing a record 1:100 reverse split just to save his salary? Some live with the lie until they die, wouldn't you agree?
So go ahead and bash me for making some lunch money on two day swing trades. I won't short it because it's a bit of a risk for me. The technicals support very short swing trades for the next couple of years. This company has never made a dime of profit in 25 years no matter what other baloney comes out of Dodd's mouth!
It all depends on the OS and what the full analysis is. Even then, look for clues that may trigger a reaction by the FDA/EMA. Passing a Phase 3 trial does not equate to new drug approval, and it certainly does not mean instant revenue. It just means it passed Phase 3 towards an NDA submittal.
I think it's a shame of all the shenanigans on this board, the endless pumping by the minute. There is very little chance that a drug goes from pre clinical to being marketed and even then a company can tank because they don't align the right partnerships, competition, regulations, etc. It's a huge risk so better prepare to not need that money for the kids education. Dodd is in his 3rd year and he doesn't have much track record on results. The money being generated on commissions does not cover the expense outlay. With this being said, dilution is in the future.
The market cap is a fair value for the company at this moment. If the company passes a phase 3, they are better off selling the company for 10x and let some other company take it to market. Just so you know, I bet big on the perifosine phase 3 and the trial did not meet endpoints. It was a large risk however if the perifosine trial passed then the company would've been in a lot better shape. Now I view this company, and its actions, as a short term lunch money play and a write off. However, I could be wrong. But my experience with the biotechs is that even with approved, marketable drugs, companies are still getting clocked because of poor management which screw the shareholders. It is what it is!
Well, I dumped and made $700 in lunch money this week. I needed your money because I was running low on fine dining funds....
I'm not sure if he will answer you because your question doesn't make sense. You can't make revenue on Phase 3 trials. Excluding the trials, the company will take a loss this year because their sales commissions will not outperform operating expenses. So, with a loss this year, look forward to the ATM cranking up and floating another 10 million shares into the pool.
I'll be dumping within the first 30 minutes of trading, cashing in the lunch money, and buy back towards $3 for another round of lunch money. Btw, whatever happened to Estrolube; I didn't see it in the report....
So the pre split share count went from 700 million to 1.2 billion? About the only thing that works for this company is the ATM.....
What's the float count? Are you absolutely certain that the company raided the ATM when they said that they weren't going to?
Unrealized revenue (ordered but not delivered) was pretty substantial this quarter, according to the CFO. It'll be interesting to see how this will be factored into the next quarter's estimates.
They used it all up in the prior conference meetings. No revenue but it sure put a lot of smiles on the team's faces.
looking for another swing trade to pay for lunch into next week. It's good for a $.20 swing and my family/friends appreciate it when I treat them for a good lunch with dessert.
I'm just doing what Dodd does, but on a smaller scale instead of Long Islands for the crew in Hilton Head. All of this marketing hype with no delivered revenue makes this an easy swing trade. It's a good swing trade cycle way into next year.
I'll buy in around $.035 pre split.....
Whispers number is loss of $.51 and looks like VVUS will report loss at $.21. The road to profitability continues. Let's see the updates on the marketing strategy.
I don't understand your question being that Carl owns the convertible notes? Please elaborate....